Compare TRNR & SCNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRNR | SCNI |
|---|---|---|
| Founded | 2017 | 2003 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Appliances | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0M | 2.6M |
| IPO Year | 2023 | N/A |
| Metric | TRNR | SCNI |
|---|---|---|
| Price | $0.62 | $1.00 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 2.6M | 46.0K |
| Earning Date | 11-14-2025 | 03-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.26 |
| Revenue | ★ $9,774,000.00 | $1,147,000.00 |
| Revenue This Year | $245.67 | N/A |
| Revenue Next Year | $308.85 | N/A |
| P/E Ratio | ★ N/A | $3.79 |
| Revenue Growth | 207.36 | ★ 303.87 |
| 52 Week Low | $0.61 | $0.61 |
| 52 Week High | $39.60 | $6.18 |
| Indicator | TRNR | SCNI |
|---|---|---|
| Relative Strength Index (RSI) | 24.69 | 60.15 |
| Support Level | $0.64 | $0.78 |
| Resistance Level | $1.62 | $0.96 |
| Average True Range (ATR) | 0.15 | 0.08 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 0.66 | 90.33 |
Interactive Strength Inc provides an integrated home fitness platform that allows its customers to participate in interactive wellness and strength-based training sessions. Its health coaching services encompass guidance and coaching on nutrition, recovery, sleep, and other health and lifestyle categories. The company generates revenue from sales of its connected fitness products, membership revenue, and personal training revenue.
Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units, one focused on in-house development of inflammation and immunology (I&I) biological therapeutic products beginning with a pipeline of nanosized VHH antibodies (NanoAbs) targeting diseases with large unmet medical needs, and the other a boutique CDMO providing services to help biotech companies efficiently bring their products to market by leveraging Scinai's drug development and GMP and non-GMP manufacturing capabilities for pre-clinical and clinical studies. The company generates maximum revenue from the provision of CDMO (Contract Development and Manufacturing Organization) services.